A Study of FAZ053 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT02936102 |
Recruitment Status :
Active, not recruiting
First Posted : October 18, 2016
Last Update Posted : March 15, 2024
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
The purpose of this "first-in-human" study of FAZ053 is to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and antitumor activity of FAZ053 administered Intravenously (i.v.)as a single agent or in combination with PDR001 in adult patients with advanced solid tumors.
By blocking the interaction between Programmed Death Ligand-1 (PD-L1) and its receptors, Programmed Death-1 (PD-1) and B7.1, FAZ053 inhibits the PD-L1 immune checkpoint, resulting in activation of an antitumor immune response by activating effector T-cells and inhibiting regulatory T-cells.
This study has been designed as a Phase I, open-label, multi-center study with a dose escalation part of FAZ053 as single agent and in combination with PDR001, followed by a dose expansion part of FAZ053 as single agent.
FAZ053 will initially be dosed every three weeks. A less frequent dosing regimen such as every 6 weeks may be evaluated in parallel.
A patient may continue treatment with FAZ053 single agent or in combination with PDR001 until the patient experiences unacceptable toxicity, confirmed disease progression per immune related Response Criteria and/or treatment is discontinued at the discretion of the investigator or the patient.
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Advanced Solid Tumors Triple Negative Breast Cancer Chordoma and Alveolar Soft Part Sarcoma | Drug: FAZ053 Drug: PDR001 | Phase 1 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 154 participants |
Allocation: | Non-Randomized |
Intervention Model: | Parallel Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | A Phase I, Open-label, Multi-center Dose Escalation Study of FAZ053 as Single Agent and in Combination With PDR001 in Adult Patients With Advanced Malignancies |
Actual Study Start Date : | October 20, 2016 |
Estimated Primary Completion Date : | November 14, 2024 |
Estimated Study Completion Date : | November 14, 2024 |
Arm | Intervention/treatment |
---|---|
Experimental: FAZ053 single agent |
Drug: FAZ053
Anti-PD-L1 Antibody |
Experimental: FAZ053 + PDR001 |
Drug: FAZ053
Anti-PD-L1 Antibody Drug: PDR001 Anti-PD-1 Antibody |
- Number of participants with Adverse Events (AEs) and Serious Adverse Events (SAEs) [ Time Frame: throughout the study and up to 150 days after end of treatment (up to approximately 46 months) ]Incidence and severity of AEs and SAEs by treatment group, including changes in vital signs, electrocardiograms (ECGs) and laboratory parameters qualifying and reported as AEs.
- Incidence of Dose Limiting Toxicities (DLTs) [ Time Frame: 21 days (single agent FAZ053) and 42 days (FAZ053+PDR001) ]A DLT is defined as an adverse event or abnormal laboratory value of Common Terminology Criteria for Adverse Events (CTCAE) grade ≥ 3 assessed as unrelated to disease, disease progression, inter-current illness or concomitant medications, which occurs within the first 21 days of treatment with FAZ053 alone or within the first 42 days when FAZ053 is given in combination with PDR001 during the dose escalation part of the study. Other clinically significant toxicities may be considered to be DLTs, even if not CTCAE grade 3 or higher.
- Dose interruptions and reductions [ Time Frame: Up to approximately 41 months ]Number of participants with dose interruptions and reductions as a measure of tolerability.
- Dose intensity [ Time Frame: Up to approximately 41 months ]Dose intensity is defined as actual dose received divided by actual duration of exposure.
- Serum concentration-time profiles of FAZ053 as single agent and FAZ053 in combination with PDR001. [ Time Frame: 41 months ]
- Presence of anti-FAZ053 and anti-PDR001. [ Time Frame: 41 months ]
- Concentration of anti-FAZ053 and anti-PDR001. [ Time Frame: 41 months ]
- Receptor Occupancy (RO) profiles when FAZ053 is given as single agent. [ Time Frame: 41 months ]
- Total soluble/shed PD-L1 concentration-time profiles when FAZ053 is given as single agent and for FAZ053 in combination with PDR001. [ Time Frame: 41 months ]
- Histopathology of tumor infiltrating lymphocytes (TILs) by hematoxylin. [ Time Frame: 41 months ]
- Histopathology of tumor infiltrating lymphocytes (TILs) by eosin (H&E) stain. [ Time Frame: 41 months ]
- Overall response rate (ORR) per RECIST v1.1 [ Time Frame: 41 months ]
- Best overall response per RECIST v1.1 [ Time Frame: 41 months ]
- Disease control rate per RECIST 1.1 [ Time Frame: 41 months ]
- Progression free survival (PFS) per RECIST 1.1 [ Time Frame: 41 months ]
- Duration of response per RECIST 1.1 [ Time Frame: 41 months ]
- Overall response rate (ORR) per immune related Response Criteria (irRC). [ Time Frame: 41 months ]
- Progression free survival (PFS) per immune related Response Criteria (irRC). [ Time Frame: 41 months ]
- Characterization of Tumor Infiltrating Lymphocytes (TILs) by Immunohistochemistry (IHC) [ Time Frame: 41 months ]
- Characterization of myeloid cell infiltrate by IHC. [ Time Frame: 41 months ]
- Area under the curve (AUC) for FAZ053 as single agent and FAZ053 in combination with PDR001. [ Time Frame: 41 months ]
- Cmax for FAZ053 as single agent and FAZ053 in combination with PDR001. [ Time Frame: 41 months ]
- Tmax for FAZ053 as single agent and FAZ053 in combination with PDR001. [ Time Frame: 41 months ]
- Half-life for FAZ053 as single agent and FAZ053 in combination with PDR001. [ Time Frame: 41 months ]
- Clast for FAZ053 as single agent and FAZ053 in combination with PDR001. [ Time Frame: 41 months ]
- Tlast for FAZ053 as single agent and FAZ053 in combination with PDR001. [ Time Frame: 41 months ]
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Written informed consent prior to any procedure.
- Dose escalation cohorts of FAZ053 single agent and FAZ053 in combination with PDR001: Patients with advanced/metastatic solid tumors with measurable or non-measurable disease as determined by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 who may or may not have received prior treatment with an immune checkpoint inhibitor, who have progressed despite standard therapy, or for whom no standard therapy is available.
- Dose expansion groups of FAZ053 single agent: Patients with advanced/metastatic solid tumors with at least one measurable lesion as determined by RECIST version 1.1 who may or may not have received prior treatment with an immune checkpoint inhibitor (for FAZ053 single agent no treatment with an anti-PD-L1 inhibitor is permitted), who have progressed despite standard therapy, or for whom no standard therapy is available and fit into one of the following groups:
- FAZ053 single agent: TNBC/ Chordoma/ ASPS
- Performance Status (PS) ≤ 2:
- Patient must have a site of disease amenable to biopsy and be a candidate for tumor biopsy according to the treating institution's guidelines. Patient must be willing to undergo a new tumor biopsy at screening/ baseline and during therapy on this study.
Exclusion Criteria:
- Presence of symptomatic central nervous system (CNS) metastases or CNS metastases that require local CNS-directed therapy (e.g. radiotherapy or surgery) or increasing doses of corticosteroids within the prior 2 weeks. Patients with treated brain metastases should be neurologically stable (for 4 weeks post-treatment and prior to study enrollment) and off of steroids for at least 2 weeks before administration of any study treatment.
- History of severe hypersensitivity to study treatment excipients and additives or other monoclonal antibodies (mAbs) and/or their excipients.
- Active, known or suspected autoimmune disease. Patients with vitiligo, residual hypothyroidism only requiring hormone replacement, psoriasis not requiring systemic treatment or conditions not expected to recur in the absence of an external trigger should not be excluded. Patients previously exposed to anti-PD-1/PD-L1 treatment who are adequately treated for skin rash or with replacement therapy for endocrinopathies should not be excluded.
- Treatment with cytotoxic or targeted antineoplastics within 3 weeks of initiation of study treatment. For cytotoxic agents that have major delayed toxicity a washout period of one cycle is indicated (examples are nitrosoureas and mitomycin C which typically require a 6 week washout). Prior antibodies or immunotherapies require a 6 week washout.
- Patients receiving systemic chronic steroid therapy or any immunosuppressive therapy (≥ 10mg/day prednisone or equivalent). Topical, inhaled, nasal and ophthalmic steroids are allowed.
- Active infection requiring systemic antibiotic therapy.
Other protocol-defined inclusion/exclusion criteria may apply.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02936102
United States, New York | |
Memorial Sloan Kettering Cancer Ctr . | |
New York, New York, United States, 10065 | |
United States, Texas | |
UT MD Anderson Cancer Center | |
Houston, Texas, United States, 77030 | |
Canada, Ontario | |
Novartis Investigative Site | |
Toronto, Ontario, Canada, M5G 2M9 | |
France | |
Novartis Investigative Site | |
Toulouse, France, 31059 | |
Israel | |
Novartis Investigative Site | |
Tel Aviv, Israel, 6423906 | |
Italy | |
Novartis Investigative Site | |
Milano, MI, Italy, 20133 | |
Novartis Investigative Site | |
Modena, MO, Italy, 41124 | |
Japan | |
Novartis Investigative Site | |
Koto ku, Tokyo, Japan, 135 8550 | |
Singapore | |
Novartis Investigative Site | |
Singapore, Singapore, 119228 | |
Spain | |
Novartis Investigative Site | |
Sevilla, Andalucia, Spain, 41013 | |
Novartis Investigative Site | |
Barcelona, Catalunya, Spain, 08035 | |
Taiwan | |
Novartis Investigative Site | |
Taipei, Taiwan, 10002 |
Study Director: | Novartis Pharmaceuticals | Novartis Pharmaceuticals |
Responsible Party: | Novartis Pharmaceuticals |
ClinicalTrials.gov Identifier: | NCT02936102 |
Other Study ID Numbers: |
CFAZ053X2101 2016-001470-15 ( EudraCT Number ) |
First Posted: | October 18, 2016 Key Record Dates |
Last Update Posted: | March 15, 2024 |
Last Verified: | March 2024 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Studies a U.S. FDA-regulated Drug Product: | Yes |
Studies a U.S. FDA-regulated Device Product: | No |
Phase I FAZ053 PDR001 |
Checkpoint inhibitor PD-L1 PD-1 |
Triple Negative Breast Neoplasms Chordoma Sarcoma, Alveolar Soft Part Neoplasms Sarcoma Neoplasms, Connective and Soft Tissue Neoplasms by Histologic Type Breast Neoplasms Neoplasms by Site |
Breast Diseases Skin Diseases Neoplasms, Germ Cell and Embryonal Neoplasms, Muscle Tissue Spartalizumab Immune Checkpoint Inhibitors Molecular Mechanisms of Pharmacological Action Antineoplastic Agents, Immunological Antineoplastic Agents |